SERUM PSA AFTER ANTIANDROGEN THERAPY

This publication has 26 references indexed in Scilit:

• The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer
  British Journal of Cancer, 1992
• Response to second-line hormonal manipulation monitored by serum PSA in stage D2 prostate carcinoma
  Urology, 1992
• Hormonal regulation of prostate‐specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP
  The Prostate, 1992
• Effect of Finasteride, a 5α-Reductase Inhibitor on Prostate Tissue Androgens and Prostate-Specific Antigen*
  Journal of Clinical Endocrinology & Metabolism, 1990
• High-dose intravenous estrogen therapy in advanced prostatic carcinoma
  Urology, 1989
• Changes in prostate-specific markers under chronic gonadotrophin-releasing hormone analogue treatment of stage D prostatic cancer
  Cancer, 1989
• The Usefulness of Prostate-Specific Antigen and Prostatic Acid Phosphatase in Clinical Practice
  American Journal of Clinical Oncology, 1988
• Biochemical Monitoring of Carcinoma of Prostate Treated with an LH‐RH Analogue (Zoladex)
  British Journal of Urology, 1986
• Changes in immunohistochemical staining in prostatic adenocarcinoma following diethylstilbestrol therapy
  The Prostate, 1985
• Criteria for Evaluating Patient Responses to Treatment Modalities for Prostatic Cancer
  Urologic Clinics of North America, 1984